PL336305A1 - 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolynones useful as inhibitors of inverse hiv transcriptase - Google Patents

4,4-disubstituted-3,4-dihydro-2(1h)-quinazolynones useful as inhibitors of inverse hiv transcriptase

Info

Publication number
PL336305A1
PL336305A1 PL98336305A PL33630598A PL336305A1 PL 336305 A1 PL336305 A1 PL 336305A1 PL 98336305 A PL98336305 A PL 98336305A PL 33630598 A PL33630598 A PL 33630598A PL 336305 A1 PL336305 A1 PL 336305A1
Authority
PL
Poland
Prior art keywords
quinazolynones
disubstituted
dihydro
inverse
inhibitors
Prior art date
Application number
PL98336305A
Inventor
Jeffrey W Corbett
Soo Sung Ko
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of PL336305A1 publication Critical patent/PL336305A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL98336305A 1997-04-09 1998-04-07 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolynones useful as inhibitors of inverse hiv transcriptase PL336305A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83854097A 1997-04-09 1997-04-09
US7132298P 1998-01-14 1998-01-14

Publications (1)

Publication Number Publication Date
PL336305A1 true PL336305A1 (en) 2000-06-19

Family

ID=26752095

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98336305A PL336305A1 (en) 1997-04-09 1998-04-07 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolynones useful as inhibitors of inverse hiv transcriptase

Country Status (19)

Country Link
EP (1) EP0973753A2 (en)
JP (1) JP2002504095A (en)
KR (1) KR20010006146A (en)
CN (1) CN1252063A (en)
AR (1) AR012340A1 (en)
AU (1) AU734928B2 (en)
BR (1) BR9808513A (en)
CA (1) CA2284996A1 (en)
EA (1) EA001991B1 (en)
EE (1) EE9900452A (en)
HR (1) HRP980143A2 (en)
HU (1) HUP0001446A3 (en)
IL (1) IL132188A0 (en)
NO (1) NO314936B1 (en)
NZ (1) NZ500592A (en)
PL (1) PL336305A1 (en)
SK (1) SK137899A3 (en)
TW (1) TW587078B (en)
WO (1) WO1998045276A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3199099A (en) * 1998-03-27 1999-10-18 Du Pont Pharmaceuticals Company 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors
AU6508899A (en) 1998-10-13 2000-05-01 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent
US6225317B1 (en) * 1998-11-19 2001-05-01 Dupont Pharmaceuticals Company Crystalline (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H)-quinazolinone
AU1821900A (en) * 1998-11-19 2000-06-05 Du Pont Pharmaceuticals Company Process for the preparation of quinazolinones
US6175009B1 (en) 1999-11-18 2001-01-16 Dupont Pharmaceuticals Company Process for the preparation of quinazolinones
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
DE60023025T2 (en) 1999-11-23 2006-07-13 Smithkline Beecham Corp. 3,4-DIHYDRO- (1H) CHINAZOLIN-2-ON COMPOUNDS AS CSBP / P39 KINASE INHIBITORS
US6555686B2 (en) * 2000-03-23 2003-04-29 Bristol-Myers Squibb Pharma Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
AU2001249161A1 (en) * 2000-03-23 2001-10-03 Bristol-Myers Squibb Pharma Company Asymmetric synthesis of quinazolin-2-ones useful as hiv reverse transcriptase inhibitors
ZA200300255B (en) 2000-07-20 2004-09-28 Bristol Myers Squibb Pharma Co Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors.
US6596729B2 (en) * 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7713214B2 (en) 2002-04-19 2010-05-11 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
AU2003295940A1 (en) * 2002-12-16 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of hiv infection through combined administration of tipranavir and capravirine
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US8282576B2 (en) 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
US9351680B2 (en) 2003-10-14 2016-05-31 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a variable user interface
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
EP1751546A2 (en) 2004-05-20 2007-02-14 Albatros Technologies GmbH & Co. KG Printable hydrogel for biosensors
WO2005120365A1 (en) 2004-06-03 2005-12-22 Pelikan Technologies, Inc. Method and apparatus for a fluid sampling device
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9386944B2 (en) 2008-04-11 2016-07-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte detecting device
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
CN102060786A (en) * 2011-01-20 2011-05-18 天津大学 4-(substituted-1,3-diyne)-4-(trifluoromethyl)-3,4-dihydro substituted quinazoline-2-ketone compound as well as preparation method and application thereof
JP6054370B2 (en) * 2011-04-06 2016-12-27 バイオヴァクシム・リミテッド Pharmaceutical composition for preventing and / or treating HIV disease in humans
JP6171003B2 (en) 2012-05-24 2017-07-26 ノバルティス アーゲー Pyrrolopyrrolidinone compounds
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
KR20160012194A (en) 2013-05-27 2016-02-02 노파르티스 아게 Imidazopyrrolidinone derivatives and their use in the treatment of disease
WO2014191906A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
AU2014272700B2 (en) 2013-05-28 2016-12-01 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
AU2014351413B2 (en) 2013-11-21 2017-06-01 Novartis Ag Pyrrolopyrrolone derivatives and their use as BET inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
AU2436792A (en) * 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
WO1993022292A1 (en) * 1992-05-07 1993-11-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5519021A (en) * 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4320347A1 (en) * 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazoline derivatives and medicaments containing them
GB2281297A (en) * 1993-08-27 1995-03-01 Merck & Co Inc Quinazoline compounds
AU1046895A (en) * 1993-11-05 1995-05-23 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5434152A (en) * 1993-11-08 1995-07-18 Merck & Co., Inc. Asymmetric synthesis of (S)-(-)-6-chloro-4- cyclopropyl-3,4-dihydro-4-[(2-pyridyl)ethynyl]-2(1H)-quinazolinone

Also Published As

Publication number Publication date
BR9808513A (en) 2000-05-23
CN1252063A (en) 2000-05-03
HUP0001446A2 (en) 2001-05-28
AU6796098A (en) 1998-10-30
NZ500592A (en) 2001-09-28
HUP0001446A3 (en) 2001-11-28
AR012340A1 (en) 2000-10-18
CA2284996A1 (en) 1998-10-15
NO994904D0 (en) 1999-10-08
KR20010006146A (en) 2001-01-26
EE9900452A (en) 2000-04-17
EP0973753A2 (en) 2000-01-26
IL132188A0 (en) 2001-03-19
HRP980143A2 (en) 1999-02-28
NO314936B1 (en) 2003-06-16
EA199900907A1 (en) 2000-04-24
SK137899A3 (en) 2000-05-16
AU734928B2 (en) 2001-06-28
EA001991B1 (en) 2001-10-22
WO1998045276A3 (en) 1999-01-14
NO994904L (en) 1999-12-01
TW587078B (en) 2004-05-11
WO1998045276A2 (en) 1998-10-15
JP2002504095A (en) 2002-02-05

Similar Documents

Publication Publication Date Title
PL336305A1 (en) 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolynones useful as inhibitors of inverse hiv transcriptase
SG80631A1 (en) Inhibitors of hiv reverse transcriptase
AU1694295A (en) Benzoxazinones as inhibitors of hiv reverse transcriptase
PL338563A1 (en) Substituted derivatives of 1,2,3,4-tetrahydronaphtalene
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
PT945443E (en) HIV INHIBITOR PYRIMIDINE DERIVATIVES
PL346005A1 (en) Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors
PT921125E (en) DERIVATIVES OF 1,38-TRIAZA-ESPIRO 4,5 DECAN-4-ONA
EP1086091A4 (en) Hiv integrase inhibitors
PL330277A1 (en) Derivatives of 2,4-diaminopyrimidine
DZ2576A1 (en) Parenteral compositions of alatrofloxacin.
PL342060A1 (en) Derivatives of 1,3,4-oxadiaxolone
ID18865A (en) METAL COMPOSITION OF WORKING METAL
AU3199099A (en) 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors
AU4698399A (en) 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9706652D0 (en) Inhibitors of FPT as anti-inflammatories
GR3033316T3 (en) Substituted 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders
AU4719799A (en) Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
GB9815925D0 (en) HIV Intergrase inhibitors
EP1023281A4 (en) Hiv integrase inhibitors
HU9502509D0 (en) Use of 1,4-dihydropyridine-3,5-dicarboxylic-acid-esters as active component of pharmaceutical compositions
NO992501D0 (en) Process for the preparation of 2-amine-2-imidazoline, guanidine and 2-amine-3,4,5,6-tetrahydropyrimidine derivatives
AU3339797A (en) 4h-3,1-benzoxazin-4-one derivatives and analogs as antiviral agents
ZA9810319B (en) Process for the preparation of acetal derivatives of 1,4-dihydropyridines, novel acetal derivatives and the use of the acetal derivatives for the preparation of other 1,4-dihydropyridines.
TW331770U (en) Engaging structure of working table